Version July 2025
Tinea corporis (ringworm): Children and Adolescents: Limited data available in ages <2 years: Topical: Apply to affected and surrounding area(s) twice daily until clinical resolution, typically 2 to 4 weeks (Ref).
Tinea cruris (jock itch): Children and Adolescents: Limited data available in ages <2 years: Topical: Apply to affected and surrounding area(s) twice daily until clinical resolution, typically 2 to 4 weeks (Ref).
Tinea pedis (athlete's foot):
Treatment: Children and Adolescents: Limited data available in ages <2 years: Topical: Apply to affected and surrounding area(s) twice daily until clinical resolution, typically 4 weeks (Ref).
Prevention: Children ≥2 years and Adolescents: Topical: Apply once or twice daily (Ref).
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
(For additional information see "Tolnaftate: Drug information")
Tinea infection:
Tinea corporis/tinea cruris: Topical: Apply to affected and surrounding area(s) twice daily until clinical resolution, typically 1 to 4 weeks (Ref).
Tinea pedis (labeled use)/tinea manuum (off-label use):
Treatment: Topical: Apply to affected and surrounding area(s) twice daily until 1 week after clinical resolution, typically for 4 weeks total (Ref).
Prevention (tinea pedis only): Topical: Apply once or twice daily.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Contact dermatitis, pruritus, stinging of the skin
Local: Irritation
OTC labeling: When used for self-medication, do not use on children <2 years of age.
Concerns related to adverse effects:
• Irritation: Discontinue if sensitivity or irritation occurs.
Other warnings/precautions:
• Self-medication (OTC use): When used for self-medication (OTC use), contact health care provider if condition does not improve within 4 weeks. Avoid contact with eyes. Not effective on the scalp.
Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Aerosol, External:
Tinactin: 1% (150 g [DSC])
Aerosol Powder, External:
Tinactin: 1% (133 g [DSC])
Tinactin Deodorant: 1% (133 g [DSC])
Cream, External:
Antifungal (Tolnaftate): 1% (14.18 g) [odorless]
FT Antifungal: 1% (15 g)
Fungi-Guard: 1% (15 g)
Tinactin: 1% (15 g [DSC], 30 g [DSC])
TriTolnacide C: 1% (37 mL) [contains butylparaben, cetyl alcohol, ethylparaben, isobutylparaben, methylparaben, propylene glycol, propylparaben]
Generic: 1% (14 g, 14.18 g, 15 g, 20 g, 28 g, 28.3 g, 30 g)
Powder, External:
Anti-Fungal: 1% (45 g [DSC])
Generic: 1% (45 g)
Solution, External:
Dr Gs Clear Nail: 1% (18 mL) [contains propylene glycol]
Formula 3 The Treatment: 1% (15 mL) [contains butylparaben, methylparaben, propylparaben, sesame oil]
Formula 7 The Solution: 1% (15 g) [contains disodium edta]
Fungicure: 1% (30 mL) [contains isopropyl alcohol]
Micomitin: 1% (30 mL) [contains benzyl alcohol]
Micotrin AL: 1% (30 mL) [contains benzyl alcohol]
Mycocide Clinical NS: 1% (30 mL) [contains propylene glycol]
Mycozyl AL: 1% (10 mL, 30 mL) [contains benzyl alcohol]
Tinaspore: 1% (10 mL)
TM-Tolnaftate: 1% (30 mL [DSC], 45 mL [DSC])
TM-Tolnaftate LR: 1% (45 mL [DSC]) [contains cetearyl alcohol, isopropyl alcohol]
Tolnafi-AL: 1% (30 mL)
TriTolnacide S: 1% (15 mL) [contains butylparaben, ethylparaben, isobutylparaben, methylparaben, propylparaben]
May be product dependent
Cream (Tolnaftate External)
1% (per gram): $0.15 - $0.29
Cream (TriTolnacide C External)
1% (per mL): $26.89
Powder (Tolnaftate External)
1% (per gram): $0.06 - $0.08
Solution (Formula 3 The Treatment External)
1% (per mL): $1.08
Solution (Formula 7 The Solution External)
1% (per gram): $1.36
Solution (Micomitin External)
1% (per mL): $56.50
Solution (Micotrin AL External)
1% (per mL): $75.00
Solution (Mycozyl AL External)
1% (per mL): $110.00
Solution (TriTolnacide S External)
1% (per mL): $63.68
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Topical: For external use only; avoid contact with eyes. Wash and dry affected area before drug application. For tinea infections, apply to surrounding areas (~1 to 2 cm beyond lesion border) in addition to affected area (Ref). For tinea pedis, pay special attention to spaces between the toes.
Aerosol, aerosol powder, solution: Shake well prior to use.
Topical: For external use only; avoid contact with eyes. Wash and dry affected area before drug application. Ensure coverage of nail edges, cuticles, and skin around the nails. For tinea pedis, also apply to spaces between the toes.
Aerosol, aerosol powder: Shake well prior to use.
Aerosol, aerosol powder, cream, liquid, powder: Store at 20°C to 25°C (68°F to 77°F). Store away from excessive heat, direct light, and cold. Do not puncture, break, or burn the aerosol powder or aerosol solution container. Do not store at temperatures above 48.9°C (120°F).
Solution: Store at 15°C to 30°C (59°F to 86°F). Store away from excessive heat, direct light, and cold. The solution solidifies at low temperatures and liquifies readily when warmed, retaining its potency. Protect from freezing.
Treatment of tinea pedis, tinea cruris, and tinea corporis (OTC products: FDA approved in ages ≥2 years and adults). Note: Topical therapy is not effective for infection of the scalp or nails. Indications vary by product; consult product-specific labeling for indications.
Tinactin may be confused with Talacen
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
There are no known significant interactions.
New skin irritation.
Distorts the hyphae and stunts mycelial growth in susceptible fungi
Onset of action: 24 to 72 hours
